Promoter methylation of the bone morphogenetic protein 6 gene in multiple myeloma

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 825-830

  Hashida, Yumiko ^a   Nemoto, Yuiko ^a   Imajoh, Masayuki ^a   Murakami, Masanao ^a   Taniguchi, Ayuko ^a   Komatsu, Naoki ^a   Yokoyama, Akihito ^a   Daibata, Masanori ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

BMP6; Methylation; Multiple myeloma; Plasmacytoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; LACTATE DEHYDROGENASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; BONE MORPHOGENETIC PROTEIN 6 GENE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE EXTRAMEDULLARY PLASMACYTOMA; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TRANSCRIPTION INITIATION SITE;

ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 6; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE SILENCING; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMACYTOMA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA;

EID: 84856247115     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1548     Document Type: Article

References (40)

1. Palumbo A and Anderson K: Multiple myeloma. N Engl J Med 364: 1046-1060, 2011.
2. Sher T, Miller KC, Deeb G, Lee K and Chanan-Khan A: Plasma cell leukemia and other aggressive plasma cell malignancies. Br J Haematol 150: 418-427, 2010.
3. Bergsagel PL and Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23: 6333-6338, 2005. (Pubitemid 46218843)
4. Munshi NC and Avet-Loiseau H: Genomics in multiple myeloma. Clin Cancer Res 17: 1234-1242, 2011.
5. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG and Osieka R: DNA methylation changes in multiple myeloma. Leukemia 18: 1687-1692, 2004. (Pubitemid 39386348)
6. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC and Huang DP: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89: 2500-2506, 1997. (Pubitemid 27143298)
7. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM and Morgan GJ: Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117: 553-562, 2011.
8. Miyazono K, Maeda S and Imamura T: BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16: 251-263, 2005. (Pubitemid 40910315)
9. Bhatia M, Bonnet D, Wu D, Murdoch B, Wrana J, Gallacher L and Dick JE: Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med 189: 1139-1148, 1999.
10. Blanco CM, Bolós FV, Medina VV, Aparicio GG, Diaz PS and Grande PE: Biology of BMP signalling and cancer. Clin Transl Oncol 11: 126-137, 2009.
11. Kodach LL, Wiercinska E, de Miranda NF, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, Hommes DW, Ten Dijke P, Offerhaus GJ and Hardwick JC: The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 134: 1332-1341, 2008.
12. Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ and Sutherland RL: Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 59: 234-242, 2004. (Pubitemid 38509755)
13. Wen XZ, Akiyama Y, Baylin SB and Yuasa Y: Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 25: 2666-2673, 2006.
14. Dai Z, Lakshmanan RR, Zhu WG, Smiraglia DJ, Rush LJ, Frühwald MC, Brena RM, Li B, Wright FA, Ross P, Otterson GA and Plass C: Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia 3: 314-323, 2001. (Pubitemid 32801881)
15. Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, Tannehill-Gregg S, Morrison CD, Auer H, Kratzke RA, Niehans G, Amatschek S, Sommergruber W, Leone GW, Rosol T, Otterson GA and Plass C: Bone morphogenetic protein 3B silencing in non-small cell lung cancer. Oncogene 23: 3521-3529, 2004. (Pubitemid 38658418)
16. Kraunz KS, Nelson HH, Liu M, Wiencke JK and Kelsey KT: Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. Br J Cancer 93: 949-952, 2005. (Pubitemid 41487023)
17. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A and Borset M: Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23: 3024-3032, 2004. (Pubitemid 38648193)
18. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, Koseki T, Nishihara T and Ikeda Y: Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96: 2005-2011, 2000.
19. Hjertner Ö, Hjorth-Hansen H, Börset M, Seidel C, Waage A and Sundan A: Bone morphogenetic protein-4 inhibits proliferation and induces apoptois of multiple myeloma cells. Blood 97: 516-522, 2001. (Pubitemid 32060339)
20. Fukuda N, Saitoh M, Kobayashi N and Miyazono K: Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells. Oncogene 25: 3509-3517, 2006. (Pubitemid 43901672)
21. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B and Hose D: Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28: 3866-3879, 2009.
22. Tamada H, Kitazawa R, Gohji K, Kamidono S, Maeda S and Kitazawa S: Molecular cloning and analysis of the 5′-flanking region of the human bone morphogenetic protein-6 (BMP-6). Biochim Biophys Acta 1395: 247-251, 1998. (Pubitemid 28116528)
23. Daibata M, Nemoto Y, Bandobashi K, Kotani N, Kuroda M, Tsuchiya M, Okuda H, Takakuwa T, Imai S, Shuin T and Taguchi H: Promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma. Clin Cancer Res 13: 3528-3535, 2007. (Pubitemid 46955112)
24. Taniguchi A, Nemoto Y, Yokoyama A, Kotani N, Imai S, Shuin T and Daibata M: Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia. Int J Cancer 123: 1824-1831, 2008.
25. Xiong Z and Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534, 1997. (Pubitemid 27303718)
26. Drexler HG: Myeloma and plasma cell leukemia B-cell lines. In: Guide to Leukemia-Lymphoma Cell Lines. Drexler HG (ed.) eBook CD, Braunschweig, pp281-357, 2005.
27. Hatakeyama N, Daibata M, Nemoto Y, Ohtsuki Y and Taguchi H: Lactate dehydrogenase production and release in a newly established human myeloma cell line. Am J Hematol 66: 267-273, 2001. (Pubitemid 32210295)
28. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C and Lazzarino M: Incidence, presenting features and outocome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21: 325-330, 2010.
29. Dimopoulos MA, Barlogie B, Smith TL and Alexanian R: High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115: 931-935, 1991.
30. Barlogie B, Smallwood L, Smith T and Alexanian R: High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 110: 521-525, 1989. (Pubitemid 19099291)
31. Sanal SM, Yaylaci M, Mangold KA and Pantazis CG: Extensive extramedullary disease in myeloma: an uncommon variant with features of poor prognosis and dedifferentiation. Cancer 77: 1298-1302, 1996. (Pubitemid 26102327)
32. Allen SL and Coleman M: Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma. Cancer Invest 8: 417-424, 1990. (Pubitemid 20352774)
33. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K and Dimopoulos MA; Greek Myeloma Study Group: High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 85: 114-119, 2010.
34. Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E and Bradwell AR: Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 46: 110-117, 2009.
35. García-Sanz R, González-Fraile MI, Mateo G, Hernández JM, López-Berges MC, de las Heras N, Fernández-Calvo J, Ortega F, Portero JA, Bárez A, Galende J, Orfão A and San Miguel JF: Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 112: 884-889, 2004. (Pubitemid 39435276)
36. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J and Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2: Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117: 4696-4700, 2011.
37. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC and Jagannath S; International Myeloma Workshop Consensus Panel 3: Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117: 4701-4705, 2011.
38. Kawabata M, Imamura T and Miyazono K: Signal transduction by bone morphogenetic proeins. Cytokine Growth Factor Rev 9: 49-61, 1998. (Pubitemid 28280536)
39. Amoroso SR, Huang N, Roberts AB, Potter M and Letterio JJ: Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytoma. Proc Natl Acad Sci USA 95: 189-194, 1998. (Pubitemid 28103929)
40. de Carvalho F, Colleoni GWB, Almedia MSS, Carvalho AL and Vettore AL: TGFßR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer 125: 1985-1991, 2009.